Topical Hemostatic Agents in Gynecologic Surgery for Benign Indications

Area of Science:

• Surgical Innovation
• Gynecologic Surgery
• Hemostasis

Background:

• Hemostatic agents, procoagulant products, have seen increased surgical use since the mid-20th century.
• Use spans multiple surgical specialties, notably gynecology.
• Evidence suggests physician preference, not clinical necessity, is a primary driver of their utilization.

Purpose of the Study:

• To critically evaluate the evidence supporting hemostatic agent use in gynecologic surgery.
• To identify specific gynecologic scenarios where hemostatic agent application is clinically justified.
• To recommend reconsideration of hemostatic agent use in situations lacking strong clinical evidence.

Main Methods:

• Literature review of studies on hemostatic agent efficacy and safety in gynecology.
• Analysis of factors influencing regional variation in surgical practice.
• Clinical judgment assessment based on current evidence and surgical outcomes.

Main Results:

• Physician preference significantly influences hemostatic agent prescription, independent of documented clinical need.
• Overutilization of hemostatic agents in gynecology is associated with increased patient risks and avoidable healthcare expenditures.
• Specific gynecologic conditions may benefit from judicious hemostatic agent application.

Conclusions:

• Hemostatic agent use in gynecology requires a shift from preference-based decisions to evidence-based practice.
• Careful consideration of clinical necessity can mitigate risks and reduce costs associated with these agents.
• Optimizing hemostatic agent use enhances patient safety and resource allocation in gynecologic procedures.